Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Maxine Gauntlett

I joined the Oncology Clinical Trials Office (OCTO) as a Clinical Trial Administrator in January 2019. Prior to this I was a Clinical Research Practitioner at Berkshire Cancer Centre in Reading as well as  a registered hospital Pharmacy Technician.

I am currently working on 3 different oncology studies;

NEOPANC-01 - A  phase 0, pre-operative, window-of-opportunity study to assess gene expression in patients with resectable pancreatic cancer 

CEDAR - A Phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer 

OxPLoreD - Oxford Pre-cancerous Lymphoproliferative Disorders: Analysis and Interception study